Trial · NCT04777201
Results by group91
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 91
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Any Adverse Event (AE), Any Severity | 188 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Any Adverse Event (AE), Any Severity | 207 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Substudy: Faricimab PTI | Any Adverse Event (AE), Any Severity | 16 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | AEs by Severity: Mild | 114 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | AEs by Severity: Mild | 106 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Substudy: Faricimab PTI | AEs by Severity: Mild | 11 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | AEs by Severity: Moderate | 58 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | AEs by Severity: Moderate | 75 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Substudy: Faricimab PTI | AEs by Severity: Moderate | 4 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | AEs by Severity: Severe | 13 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | AEs by Severity: Severe | 23 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Substudy: Faricimab PTI | AEs by Severity: Severe | 1 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | AEs by Severity: Missing | 3 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | AEs by Severity: Missing | 3 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Substudy: Faricimab PTI | AEs by Severity: Missing | 0 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | Serious Adverse Event (SAE) | 18 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | Serious Adverse Event (SAE) | 27 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Substudy: Faricimab PTI | Serious Adverse Event (SAE) | 1 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort A: Faricimab PTI (Prior Faricimab) | AE Leading to Withdrawal from Study Treatment | 4 | Participants | |
| Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale | Main Study Cohort B: Faricimab PTI (Prior Aflibercept) | AE Leading to Withdrawal from Study Treatment | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04777201/results